Deutsche Märkte schließen in 5 Stunden 50 Minuten

Novartis AG (NVS)

NYSE - Nasdaq Echtzeitpreis. Währung in USD
Zur Watchlist hinzufügen
89,42+0,77 (+0,87%)
Börsenschluss: 04:00PM EDT
89,50 +0,08 (+0,09%)
Nachbörse: 07:44PM EDT
Melden Sie sich an, um eine Nachricht zu posten.
  • A
    $NVS $NUWE
  • H
    Optimistic about the tumor treatment business,it’s a promising industry. $SISI $NVS $PFE
  • A
    $AMRN , JT presentation today is super strong BP wake up and buyout this company even at $50B looks cheap going forward $PFE $AMGN. $NVS. $GSK spend the money it’s worth it, ADA Standard of Care , Diabetes community is a very lucrative big market 90 million of them according to JT , wow that alone counts in BILLIONS, JT always says we’re not competing in Statins $500B markets but Triglycerides and Cholesterol is entangled now that will take many BILLIONS from that, Atherosclerosis, Alzheimer’s and Cancers future collaborators are looking at that too, AMRN is severely undervalued here and should be close to $100/Shares, A game changer just like $BYND and $UBER in each industry
  • A
    Imagine Pfizer sales force selling Vascepa’s right now the $2B to $4B sales easily achieved (above 500 Triglycerides) some off label use too, Now the sNDA as we know it is 20X bigger (150 to 500) US alone, new report is China’s 185M People have very high Triglycerides, this one is massive going forward, $NVS or $PFE will have epic buyout
  • b
    bear hunter
    $TLRY conversation
    $TLRY the first company to partner with big pharma, or $NVS, this could be huge in the long run for both companies
    Marijuana stock investors are paying very close attention to markets again this week. This month investors are anticipating a final…
    Marijuana stock investors are paying very close attention to markets again this week. This month investors are anticipating a final…
  • S
    $APHA conversation
    Why did they keep the Tilray name? Because of Novartis $NVS partnership that Tilray has. Big European pharma with 700 milion population 😉😉
  • D

    DR RNAi (Harvard, MIT)

    Replying to
    $NVS takes out $ALNY
    $JNJ takes out $ARWR
  • A
    AMRN looks like ready to explode $PFE or $NVS should take advantage $80 to $100 buyout
  • T
    $ARWR conversation
    mike b and ttracer on twitter putting the puzzle together to see if novartis and arwr is a fit:

    from mike b:
    $ARWR-This is an important deal for us. Novartis has been working in the RNAi field for over a decade and their developments in proprietary oligonucleotide formatting and modifications are some of the best we've seenWe anticipate this acquisition will provide us expanded freedom

    Arrowhead acquires patents as well as intellectual property rights to Alnylam's RNAi tech, 30 gene targets Novartis has picked from its partnership and a pipeline with three candidates that had generated preclinical data $10M Cash/$25M Stock. I think this was a STEAL.

    from tsquared: CA seemed to imply years ago (when they initially purchased Novartis’s IP) that they had a favorable relationship. It remains plausible, and if that collaboration occurs, $ALNY Maraganore will never be able to walk back his colorful “phantasmagorical” description of $ARWR $NVS

    posting for mike b as he has sworn off of the board until we hit a certain target...somewhere in the 20's i believe
  • n
    $SNY conversation
    Novavax’ NanoFlu Achieves All Primary Endpoints In Phase 3 Clinical Trial. $SNY, $PFE, $JNJ, $EBS, $AZN, $NVS, $GSK
    Trial also achieves statistical significance in key secondary endpoints
    Novavax to submit a U.S. BLA under FDA’s accelerated approval pathway
    Company to host investor conference call today at 8:30 a.m. EDT
    GAITHERSBURG, Md., March 24, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced positive top-line results of its pivotal Phase 3 clinical trial of NanoFlu™, its recombinant quadrivalent seasonal influenza vaccine candidate with its proprietary Matrix-M™ adjuvant, in adults aged 65 and older. Using the Food and Drug Administration’s (FDA) criteria for accelerated approval of seasonal influenza vaccines, the trial evaluated the immunogenicity and safety of NanoFlu compared to Fluzone® Quadrivalent, a U.S.-licensed quadrivalent influenza vaccine.
  • R
    $NTLA conversation
    Varro Analytics
    There is headline risk with upcoming $NTLA in vivo liver data

    Still, don’t see $VERV going sub $1B. That’s gets into $DTIL territory, which doesn’t have name recognition of #CRISPR, no less #baseediting

    You can also surely get to $1b+ in a DCF

    And $NVS bought $MDCO for $9B
  • b
    Arrowhead Pharmaceuticals, Inc.
    Hard to believe $NVS & $ARWR are not talking to each other at this point.
  • a
    $ADRO $NVS has removed ADU-S100, an intratumoral STING pathway activator product candidate, from its portfolio based on clinical data

    Winding down enrollment of Ph1b ADU-S100 + spartalizumab in solid tumors and terminating Ph1 ADU-S100 + Yervoy in melanoma
  • S
    $AGEN conversation
    $NVS need our QS-21
    Novartis provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19

    Phase III study did not meet its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications (death, mechanical ventilation or ICU care)1
  • B
    $EXEL conversation
    If $EXEL is looking to diversify & add molecules in the clinic quickly w/ premier bi-specific Ab, then it needs to look into collaboration w/ $XNCR .Their collaboration with Genentech $RHHB Janssen $amgn $NVS
    MDAnderson morphosys $MOR Alexion $alxn Astellas (Japan) validates XNCR's technology. It's at least worth a look and there could be hugely beneficial arrangements for both parties. Xencor has very rich pipeline already and I am sure would be happy to have a partner take over some of these advanced molecules as well as with their excellent and much sought after bi-specific technology and premiere engineering platform, have many in early preclinical development. Doesn't mean EXEL needs to jump in but some due diligence and potential partnership would be time well spent. Bi-specific technology of biologics would nicely complement Exelixis' small molecule and ADC pipeline and collaborations.
  • A
    AMRN, let’s check the numbers HCW price target is $51 base on 6M target population, now with Reduced it/ CVD the new population target jump to 60M to 70M so , what’s gonna be Analysts price target now? Think BP $PFE $NVS $AMGN $AZN $BIIB $GILD $ABBV should partner or buyout, so many lives will be saved
  • A
    AMRN great news AMR 102 combo of Vascepa and Statin could start phase 3 after adcom, over $20 Monday, BP better be ready $PFE $NVS $GSK
  • A
    Buyout rumors getting louder $PFE. $GSK. $NVS. $AMGN who’s gonna win $AMRN mid target $35 to high $51 , buyout could be over $100 Boooyah
  • n
    $SNY conversation
    Novavax Identifies Coronavirus Vaccine Candidate; Accelerates Initiation of First-in-Human Trial to Mid-May $PFE, $JNJ, $GSK, $AZN, $NVS, $GILD, $EBS
    -- NVX-CoV2373 identified as SARS-CoV-2 candidate for Phase 1 clinical trial
    -- In preclinical studies, NVX-CoV2373 demonstrated high immunogenicity and stimulated high levels of neutralizing antibodies
    -- First-in-human Phase 1 clinical trial accelerated to mid-May with preliminary results in July
    -- GMP clinical production initiated at Emergent BioSolutions with ability to leverage capacity for large scale manufacturing
    GAITHERSBURG, Md., April 08, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it has identified a coronavirus vaccine candidate, NVX-CoV2373, a stable, prefusion protein made using Novavax’ proprietary nanoparticle technology, and will initiate a first-in-human trial in mid-May. Novavax’ proprietary Matrix-M™ adjuvant will be incorporated with NVX-CoV2373 in order to enhance immune responses and stimulate high levels of neutralizing antibodies.
    NVX-CoV2373 was shown to be highly immunogenic in animal models measuring spike protein-specific antibodies, antibodies that block the binding of the spike protein to the receptor and wild-type virus neutralizing antibodies. High levels of spike protein-specific antibodies with ACE-2 human receptor binding domain blocking activity and SARS-CoV-2 wild-type virus neutralizing antibodies were observed after a single immunization. In addition, the already high microneutralization titers seen after one dose increased eight fold with a second dose. High titer microneutralizing antibodies are generally accepted evidence that a vaccine is likely to be protective in humans.
  • A
    MFool sales estimates for Vascepa’s $10B in 2 to 3 years conservatives or not is pretty good start considering market cap right now is only $6B making $AMRN severely undervalued and BP knows that, $PFE $GSK or $NVS bids for the next Lipitor